Ultragenyx Pharmaceutical Inc. Stock price




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
53.69 USD +3.81% Intraday chart for Ultragenyx Pharmaceutical Inc. +8.51% +12.28%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 515M Sales 2025 * 635M Capitalization 4.42B
Net income 2024 * -534M Net income 2025 * -458M EV / Sales 2024 * 7.87 x
Net cash position 2024 * 369M Net cash position 2025 * 210M EV / Sales 2025 * 6.63 x
P/E ratio 2024 *
-8.3 x
P/E ratio 2025 *
-10.5 x
Employees 1,276
Yield 2024 *
Yield 2025 *
Free-Float 95.63%
More Fundamentals * Assessed data
Dynamic Chart
Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday MT
Wedbush Lifts Ultragenyx Pharmaceutical's PT to $48 From $47, Notes Fuller Catalyst Lineup for 2024; Keeps Neutral Rating MT
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set MT
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q4 Revenue $127.4M MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024 CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Ultragenyx Says UX111 Treatment Results Correlate With Improved Cognitive Function MT
Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) CI
Ultragenyx Pharmaceutical's Angelman Syndrome Potential Treatment Receives European Medicines Agency Priority Designation MT
Ultragenyx Pharmaceutical Inc. Receives PRIME Designation from European Medicines Agency for GTX-102 for the Treatment of Angelman Syndrome CI
Ultragenyx Pharmaceutical Doses All Patients in Stage 1 Cohorts of Trial Evaluating Wilson Disease Therapy MT
Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease CI
Transcript : Ultragenyx Pharmaceutical Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:00 PM
More news

Latest transcript on Ultragenyx Pharmaceutical Inc.

1 day+3.81%
1 week+8.51%
Current month+3.81%
1 month+21.75%
3 months+33.69%
6 months+42.11%
Current year+12.28%
More quotes
1 week
Extreme 49.09
1 month
Extreme 42.24
Current year
Extreme 41.87
1 year
Extreme 31.52
3 years
Extreme 31.52
5 years
Extreme 31.52
10 years
Extreme 31.52
More quotes
Managers TitleAgeSince
Founder 63 10-04-21
Director of Finance/CFO 47 23-10-15
Chief Tech/Sci/R&D Officer - 17-10-31
Members of the board TitleAgeSince
Director/Board Member 61 17-04-05
Founder 63 10-04-21
Chairman 66 15-04-07
More insiders
Date Price Change Volume
24-03-01 53.69 +3.81% 743,828
24-02-29 51.72 -1.95% 1,347,322
24-02-28 52.75 -1.70% 924,222
24-02-27 53.66 +6.79% 910,705
24-02-26 50.25 +1.56% 553,606

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company's four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
53.69 USD
Average target price
89.85 USD
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Ultragenyx Pharmaceutical Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.